Prognostic value of miR-96 in patients with acute myeloid leukemia
1 Department of Hematology, the First Affiliated Hospital of Sun Yat-Sen University, 510080 Guangzhou, Guangdong, China
2 Department of Hematology, Zhongshan Hospital of Xiamen University, 361004 Xiamen, Fujian, China
3 Department of Pathology, the First Affiliated Hospital of Sun Yat-Sen University, 510080 Guangzhou, Guangdong, China
4 Department of Nosocomial Infection Control Department, Zhongshan Hospital of Xiamen University, 361004 Xiamen, Fujian, China
Diagnostic Pathology 2014, 9:76 doi:10.1186/1746-1596-9-76Published: 29 March 2014
Aberrant expression of miRNA (miR)-96 is associated with tumorigenesis and tumor progression in several solid cancers. However, little is known about the expression and prognostic value of miR-96 in acute myeloid leukemia (AML). Therefore, the aim of this study was to investigate the correlation of miR-96 expression with clinicopathological features and prognosis of AML.
Real-time quantitative RT-PCR assay was performed to evaluate the expression levels of miR-96 in mononuclear cells from bone marrow or peripheral blood specimens in 86 patients with newly diagnosed AML.
Compared with normal controls, miR-96 expression was significantly downregulated in patients with newly diagnosed AML (P < 0.001). In analysis of 14 diagnosis/CR-paired samples, the expression level of miR-96 was found markedly elevated in patients after treatment than before (P < 0.001). Moreover, lower levels of miR-96 were associated with a higher white blood cell count, bone marrow blast count (P < 0.001 and 0.022, respectively), and lower hemoglobin and platelet count (P = 0.036 and 0.033, respectively). Although the low-expression group seemed to have a lower CR rate (53.85% vs 70.0%), there was no significant difference between the two groups (P = 0.213). The low-expression group had a lower relapse-free survival (RFS) (P = 0.038) and overall survival (OS) (P = 0.022) compared with the high-expression group during a median follow-up of 20 months.
Our data demonstrated that the expression of miR-96 was downregulated in newly diagnosed AML patients and associated with leukemic burden, as well as RFS and OS. This suggests that miR-96 detection might become a potential biomarker of prognosis and monitoring in AML.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1434808553949498 webcite